Nonalcoholic Fatty Liver
50
8
13
24
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
4.0%
2 terminated out of 50 trials
92.3%
+5.8% vs benchmark
12%
6 trials in Phase 3/4
33%
8 of 24 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 24 completed trials
Clinical Trials (50)
Weight, Energy, Lipids, and the Liver (WELL) Study
Digital Therapy for Fatty Liver Disease
A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)
Assessment of Fatty Liver With Thermo-acoustic Device
Identification of Liver Fibrosis Biomarkers
Effect of a GnRH Analog on Hepatic Steatosis
The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease
Accurate Point of Care Liver Disease Diagnostics
Effect of Adding TENS to Mediterranean Diet on Appetite and Liver Enzymes in Nonalcoholic Fatty Liver Patients
Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes
Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity
Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease
Safety Study of OA-235i in Subjects With Nonalcoholic Steatohepatitis
Conditionally Increased Output (CIO) Enhanced Ultrasound System
A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH
A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis
Effect of Multi-ingredient on Visceral Adiposity & Non-alcoholic Fatty Liver Disease in Postmenopausal Women With Abdominal Obesity
Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease
The Liver Health Study for Patients with NAFLD
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance